Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Lung Cancer

Free Subscription 03.12.2018 4 Ann Thorac Surg 6 BMC Cancer 1 Cancer Lett 1 Cancer Sci 3 Clin Lung Cancer 1 Clin Nucl Med 3 Int J Cancer 1 Int J Oncol 2 J Cancer Res Clin Oncol 1 J Clin Oncol 2 J Thorac Cardiovasc Surg 3 J Thorac Oncol 1 JAMA Oncol 4 Lancet Oncol 1 Lung Cancer 2 Lung Cancer (Auckl) 1 Mol Cancer Ther 1 N Engl J Med 1 Nat Med 1 Oncogene 3 Oncol Rep 1 PLoS One 1 Semin Oncol

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

Ann Thorac Surg

1. XU J, Wang S, Zhang B, Qian J, et al
   Adjuvant chemotherapy improves survival in surgically resected stage IB squamous lung cancer.
   Ann Thorac Surg. 2018 Nov 20. pii: S0003-4975(18)31669.
   PubMed     Text format     Abstract available
   
   
2. FERNANDO HC
   Comparison between stereotactic radiotherapy and sublobar resection for non-small cell lung cancer (Commentary).
   Ann Thorac Surg. 2018 Nov 24. pii: S0003-4975(18)31697.
   PubMed     Text format    
   
   
3. LOI M, Mazzella A, Mansuet-Lupo A, Bobbio A, et al
   Synchronous Oligometastatic Lung Cancer deserves a dedicated management.
   Ann Thorac Surg. 2018 Nov 23. pii: S0003-4975(18)31681.
   PubMed     Text format     Abstract available
   
   
4. NEWMAN NB, Attia A, Osmundson EC
   Response to Adding Post-Operative Adjuvant Radiation In N2 lung cancer.
   Ann Thorac Surg. 2018 Nov 21. pii: S0003-4975(18)31676.
   PubMed     Text format    
   
   

   
   BMC Cancer

5. VOLLBRECHT C, Lenze D, Hummel M, Lehmann A, et al
   RNA-based analysis of ALK fusions in non-small cell lung cancer cases showing IHC/FISH discordance.
   BMC Cancer. 2018;18:1158.
   PubMed     Text format     Abstract available
   
   
6. SINGH AK, Hennon M, Ma SJ, Demmy TL, et al
   A pilot study of stereotactic body radiation therapy (SBRT) after surgery for stage III non-small cell lung cancer.
   BMC Cancer. 2018;18:1183.
   PubMed     Text format     Abstract available
   
   
7. LIU K, Xu SH, Chen Z, Zeng QX, et al
   TRPM7 overexpression enhances the cancer stem cell-like and metastatic phenotypes of lung cancer through modulation of the Hsp90alpha/uPA/MMP2 signaling pathway.
   BMC Cancer. 2018;18:1167.
   PubMed     Text format     Abstract available
   
   
8. CHEN RL, Zhao J, Zhang XC, Lou NN, et al
   Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression.
   BMC Cancer. 2018;18:1171.
   PubMed     Text format     Abstract available
   
   
9. DE MOL M, Visser S, Aerts JGJV, Lodder P, et al
   Satisfactory results of a psychometric analysis and calculation of minimal clinically important differences of the World Health Organization quality of life-BREF questionnaire in an observational cohort study with lung cancer and mesothelioma patients
   BMC Cancer. 2018;18:1173.
   PubMed     Text format     Abstract available
   
   
10. BLUM W, Pecze L, Rodriguez JW, Steinauer M, et al
    Regulation of calretinin in malignant mesothelioma is mediated by septin 7 binding to the CALB2 promoter.
    BMC Cancer. 2018;18:475.
    PubMed     Text format     Abstract available
    
    

    
    Cancer Lett

11. TREMBLE LF, O'Brien MA, Forde PF
    Electrochemotherapy with cisplatin increases survival and induces immunogenic responses in murine models of lung cancer and colorectal cancer.
    Cancer Lett. 2018 Nov 22. pii: S0304-3835(18)30680.
    PubMed     Text format     Abstract available
    
    

    
    Cancer Sci

12. HAYASHI K, Yamamoto N, Nakajima M, Nomoto A, et al
    Clinical Outcomes of Carbon-Ion Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer.
    Cancer Sci. 2018 Nov 22. doi: 10.1111/cas.13890.
    PubMed     Text format     Abstract available
    
    

    
    Clin Lung Cancer

13. TAMURA T, Miyazaki K, Shiozawa T, Satoh H, et al
    Comparative Effectiveness and Resource Usage in Patients Receiving First-line Taxol-based Chemotherapy for Stage IV NSCLC.
    Clin Lung Cancer. 2018;19:e67.
    PubMed     Text format    
    
    
14. MA K, Zhan C, Wang S, Shi Y, et al
    Spread Through Air Spaces (STAS): A New Pathologic Morphology in Lung Cancer.
    Clin Lung Cancer. 2018 Oct 26. pii: S1525-7304(18)30268.
    PubMed     Text format     Abstract available
    
    
15. ROSSI S, Toschi L, Finocchiaro G, Di Noia V, et al
    Impact of Exon 19 Deletion Subtypes in EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer Treated With First-Line Tyrosine Kinase Inhibitors.
    Clin Lung Cancer. 2018 Nov 2. pii: S1525-7304(18)30293.
    PubMed     Text format     Abstract available
    
    

    
    Clin Nucl Med

16. WANG W, Kan Y, Liu J, Yuan L, et al
    Increased Skeletal Muscle FDG Uptake Due to Sexual Activity on PET/CT in a Middle Age Woman.
    Clin Nucl Med. 2018 Aug 27. doi: 10.1097/RLU.0000000000002228.
    PubMed     Text format     Abstract available
    
    

    
    Int J Cancer

17. WANG S, Yan B, Zhang Y, Xu J, et al
    Different characteristics and survival in non-small cell lung cancer patients with primary and acquired EGFR T790M mutation.
    Int J Cancer. 2018 Nov 25. doi: 10.1002/ijc.32015.
    PubMed     Text format     Abstract available
    
    
18. LIN YT, Chen JS, Liao WY, Ho CC, et al
    Clinical Outcomes and Secondary Epidermal Growth Factor Receptor (EGFR) T790M Mutation among First-line Gefitinib, Erlotinib and Afatinib-treated Non-small Cell Lung Cancer Patients with Activating EGFR Mutations.
    Int J Cancer. 2018 Nov 28. doi: 10.1002/ijc.32025.
    PubMed     Text format     Abstract available
    
    
19. FANIDI A, Carreras-Torres R, Larose TL, Yuan JM, et al
    Is high vitamin B12 status a cause of lung cancer?
    Int J Cancer. 2018 Nov 29. doi: 10.1002/ijc.32033.
    PubMed     Text format     Abstract available
    
    

    
    Int J Oncol

20. AHMMED B, Khan MN, Nisar MA, Kampo S, et al
    Tunicamycin enhances the suppressive effects of cisplatin on lung cancer growth through PTX3 glycosylation via AKT/NF-kappaB signaling pathway.
    Int J Oncol. 2018 Nov 28. doi: 10.3892/ijo.2018.4650.
    PubMed     Text format     Abstract available
    
    

    
    J Cancer Res Clin Oncol

21. THORLACIUS-USSING J, Kehlet SN, Ronnow SR, Karsdal MA, et al
    Non-invasive profiling of protease-specific elastin turnover in lung cancer: biomarker potential.
    J Cancer Res Clin Oncol. 2018 Nov 22. pii: 10.1007/s00432-018-2799.
    PubMed     Text format     Abstract available
    
    
22. WANG J, Wu N, Lv C, Yan S, et al
    Should patients with stage IB non-small cell lung cancer receive adjuvant chemotherapy? A comparison of survival between the 8th and 7th editions of the AJCC TNM staging system for stage IB patients.
    J Cancer Res Clin Oncol. 2018 Nov 24. pii: 10.1007/s00432-018-2801.
    PubMed     Text format     Abstract available
    
    

    
    J Clin Oncol

23. LIANG F
    Is SLFN11 a Promising Predictive Biomarker of Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Small-Cell Lung Cancer? Not Yet!
    J Clin Oncol. 2018 Nov 29:JCO1800993. doi: 10.1200/JCO.18.00993.
    PubMed     Text format    
    
    

    
    J Thorac Cardiovasc Surg

24. ZHANG Y, Chen H
    Neoadjuvant or adjuvant chemotherapy for non-small-cell lung cancer: Does the timing matter?
    J Thorac Cardiovasc Surg. 2018 Oct 12. pii: S0022-5223(18)32632.
    PubMed     Text format    
    
    
25. CAO C, Wang D, Chung C, Tian D, et al
    A systematic review and meta-analysis of stereotactic body radiation therapy versus surgery for patients with non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2018 Sep 15. pii: S0022-5223(18)32347.
    PubMed     Text format     Abstract available
    
    

    
    J Thorac Oncol

26. LICHTENSTEIN M, Nipp RD, Muzikansky A, Goodwin K, et al
    Impact of Age on Outcomes with Immunotherapy in Patients with Non-Small Cell Lung Cancer (NSCLC).
    J Thorac Oncol. 2018 Nov 23. pii: S1556-0864(18)33454.
    PubMed     Text format     Abstract available
    
    
27. FUJIMOTO D, Yoshioka H, Kataoka Y, Morimoto T, et al
    Pseudoprogression in previously treated patients with non-small cell lung cancer who received nivolumab monotherapy: A multicenter retrospective cohort study.
    J Thorac Oncol. 2018 Nov 20. pii: S1556-0864(18)33418.
    PubMed     Text format     Abstract available
    
    
28. KARACHALIOU N, Bracht JWP, Bruno MF, Drozdowskyj A, et al
    BRIEF REPORT: Association of PALB2 Messenger RNA Expression with platinum-docetaxel efficacy in advanced non-small cell lung cancer.
    J Thorac Oncol. 2018 Nov 22. pii: S1556-0864(18)33450.
    PubMed     Text format     Abstract available
    
    

    
    JAMA Oncol

29. CHEN XZ
    Anlotinib for Refractory Advanced Non-Small Cell Lung Cancer in China.
    JAMA Oncol. 2018 Nov 29. pii: 2716809. doi: 10.1001/jamaoncol.2018.5526.
    PubMed     Text format    
    
    

    
    Lancet Oncol

30. ZHONG WZ, Wang Q, Mao WM, Xu ST, et al
    Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.
    Lancet Oncol. 2018;19:139-148.
    PubMed     Text format     Abstract available
    
    
31. HERBST RS, Redman MW, Kim ES, Semrad TJ, et al
    Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study.
    Lancet Oncol. 2018;19:101-114.
    PubMed     Text format     Abstract available
    
    
32. GOURD E
    Durvalumab boosts progression-free survival in NSCLC.
    Lancet Oncol. 2018;19:e11.
    PubMed     Text format    
    
    
33. STIRRUPS R
    Osimertinib improves progression-free survival in NSCLC.
    Lancet Oncol. 2018;19:e10.
    PubMed     Text format    
    
    

    
    Lung Cancer

34. TANAKA I, Morise M, Kodama Y, Matsui A, et al
    Potential for afatinib as an optimal treatment for advanced non-small cell lung carcinoma in patients with uncommon EGFR mutations.
    Lung Cancer. 2018 Nov 14. pii: S0169-5002(18)30645.
    PubMed     Text format    
    
    

    
    Lung Cancer (Auckl)

35. ABDALLAH N, Nagasaka M, Abdulfatah E, Shi D, et al
    Non-small cell to small cell lung cancer on PD-1 inhibitors: two cases on potential histologic transformation.
    Lung Cancer (Auckl). 2018;9:85-90.
    PubMed     Text format     Abstract available
    
    
36. SATO T, Shimosato T, Klinman DM
    Silicosis and lung cancer: current perspectives.
    Lung Cancer (Auckl). 2018;9:91-101.
    PubMed     Text format     Abstract available
    
    

    
    Mol Cancer Ther

37. ZERNICKEL E, Sak A, Riaz A, Klein D, et al
    Targeting of BRM sensitizes BRG1 mutant lung cancer cell lines to radiotherapy.
    Mol Cancer Ther. 2018 Nov 26. pii: 1535-7163.MCT-18-0067.
    PubMed     Text format     Abstract available
    
    

    
    N Engl J Med

38. MANLEY C, Olszanski A
    Melanoma in the Bronchus.
    N Engl J Med. 2018;379:e36.
    PubMed     Text format    
    
    

    
    Nat Med

39. SHAH KN, Bhatt R, Rotow J, Rohrberg J, et al
    Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer.
    Nat Med. 2018 Nov 26. pii: 10.1038/s41591-018-0264.
    PubMed     Text format     Abstract available
    
    

    
    Oncogene

40. FAN Z, Yang J, Zhang D, Zhang X, et al
    The risk variant rs884225 within EGFR impairs miR-103a-3p's anti-tumourigenic function in non-small cell lung cancer.
    Oncogene. 2018 Nov 23. pii: 10.1038/s41388-018-0576.
    PubMed     Text format     Abstract available
    
    

    
    Oncol Rep

41. XU L, Du H, Zhang Q, Wang C, et al
    BAI1associated protein 2like 2 is a potential biomarker in lung cancer.
    Oncol Rep. 2018 Nov 26. doi: 10.3892/or.2018.6883.
    PubMed     Text format     Abstract available
    
    
42. LI J, Wang J, Yu J, Zhao Y, et al
    Knockdown of POLE2 expression suppresses lung adenocarcinoma cell malignant phenotypes in vitro.
    Oncol Rep. 2018;40:2477-2486.
    PubMed     Text format     Abstract available
    
    
43. LV W, Yu X, Li W, Feng N, et al
    Low expression of LINC00982 and PRDM16 is associated with altered gene expression, damaged pathways and poor survival in lung adenocarcinoma.
    Oncol Rep. 2018;40:2698-2709.
    PubMed     Text format     Abstract available
    
    

    
    PLoS One

44. GHOSH A, Sarkar S, Banerjee S, Behbod F, et al
    MIND model for triple-negative breast cancer in syngeneic mice for quick and sequential progression analysis of lung metastasis.
    PLoS One. 2018;13:e0198143.
    PubMed     Text format     Abstract available
    
    

    
    Semin Oncol

45. KING-KALLIMANIS BL, Kanapuru B, Blumenthal GM, Theoret MR, et al
    Age-related differences in patient-reported outcomes in patients with advanced lung cancer receiving anti-PD-1/PD-L1 therapy.
    Semin Oncol. 2018 Oct 25. pii: S0093-7754(18)30127.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: